Angiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapy

Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):122-123. doi: 10.1093/ehjcvp/pvz005.

Authors

Sverre E Kjeldsen^{1

2

3}, Dan Atar^{1

2}, Thomas G von Lueder^{2

4}

Affiliations

¹ Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
² Department of Cardiology, Oslo University Hospital Ullevaal, Kirkeveien 166, Oslo, Norway.
³ Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA.
⁴ Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Australia.

PMID: 30698668
DOI: 10.1093/ehjcvp/pvz005

No abstract available

Publication types

Letter

MeSH terms

Aminobutyrates / adverse effects
Aminobutyrates / therapeutic use*
Angiotensin Receptor Antagonists / adverse effects
Angiotensin Receptor Antagonists / therapeutic use*
Animals
Antihypertensive Agents / adverse effects
Antihypertensive Agents / therapeutic use*
Biphenyl Compounds
Blood Pressure / drug effects*
Clinical Decision-Making
Drug Combinations
Humans
Hypertension / diagnosis
Hypertension / drug therapy*
Hypertension / enzymology
Hypertension / physiopathology
Neprilysin / antagonists & inhibitors*
Neprilysin / metabolism
Patient Selection
Protease Inhibitors / adverse effects
Protease Inhibitors / therapeutic use*
Renin-Angiotensin System / drug effects*
Tetrazoles / adverse effects
Tetrazoles / therapeutic use*
Treatment Outcome
Valsartan

Substances

Aminobutyrates
Angiotensin Receptor Antagonists
Antihypertensive Agents
Biphenyl Compounds
Drug Combinations
Protease Inhibitors
Tetrazoles
Valsartan
Neprilysin
sacubitril and valsartan sodium hydrate drug combination